Genprex(GNPX) Prnewswire·2024-11-05 14:29Core Insights - Genprex, Inc. announced positive preclinical data for its lead drug candidate, Reqorsa® Gene Therapy, which modulates immune responses against cancer [1][2] - The findings will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting, indicating the growing evidence of Reqorsa's anti-tumor mechanisms [2][4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System [7][8] - The company collaborates with academic institutions to advance its drug candidates and has received Fast Track Designation and Orphan Drug Designation from the FDA for its lung cancer programs [8] Research Findings - The study involved TUSC2 Knock Out (KO) and Wild Type (WT) mice, analyzing immune responses through flow cytometry [2][3] - In the Reqorsa supplemented group, tumor growth was significantly reduced, with a notable decrease in T regulatory cells and an increase in Cytotoxic T cells and NK cells [3][4] - The research suggests that Reqorsa can enhance immune responses against tumors, even in individuals with low TUSC levels due to various health conditions [4][5] Product Details - Reqorsa consists of a TUSC2 gene expressing plasmid encapsulated in lipid-based nanoparticles, specifically targeting cancer cells while minimizing normal tissue uptake [5][8] - Laboratory studies indicate that the uptake of TUSC2 in tumor cells post-Reqorsa treatment is 10 to 33 times higher than in normal cells [5] Future Developments - Following the conference, the poster detailing the research will be available for download on Genprex's website [6]